Summary of HIV-1 Test Results.

<p>The figure shows the timing of test positivity in relation to the rapid antibody test (Day 0) for the Zeptometrix cohort. Each segment of the stacked bar graph represents an individual subject.</p

INT Primer and Quencher Probe Sequences.

<p>INT Primer and Quencher Probe Sequences.</p

Correlation in antibody reactivity between plasma and DBS.

a<p>Inter-assay variation, as measured by repeat testing of know Incident/Prevalent controls. CV is representative of median values for standards.</p>b<p>Median value for all samples, comparing plasma and DBS values.</p><p>Correlation in antibody reactivity between plasma and DBS.</p

Evaluation of RT-LAMP Assay with SeraCare Seroconversion Panels.

<p>+, reactive test result; -, non-reactive test result; +/-, reactive in 1 of 2 replicates; IND, indeterminate; ND, no data; *, first detectable viral load.</p><p>Evaluation of RT-LAMP Assay with SeraCare Seroconversion Panels.</p

Impact of disease progression and antiretroviral use on false-recent rates.

a<p>Includes entire MSM cohort.</p

CDC versus field DBS.

<p>The normalized MFI values and avidity index were compared for CDC versus field-prepared DBS. The solid lines represent the linear trend lines.</p

Evaluation of RT-LAMP Assay with Zeptometrix Seroconversion Panels.

<p>+, reactive test result; -, non-reactive test result; +/-, reactive in 1 of 2 replicates; IND, indeterminate; ND, no data; *, first detectable viral load.</p><p>Evaluation of RT-LAMP Assay with Zeptometrix Seroconversion Panels.</p

Correlation between plasma and DBS.

<p>The normalized MFI values (n) and avidity index (a) for plasma versus DBS were compared for all specimens. The solid line represents the linear trend line for all data points.</p

Number of recent infections.

a<p>Number of samples classified as recent out of 152 total specimens.</p><p>Number of recent infections.</p

Correlation with site-prepared DBS.

<p>Correlation with site-prepared DBS.</p